{"id":"arm-closed-dalteparin","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Elevated transaminases"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dalteparin binds to and potentiates antithrombin III, a natural anticoagulant, leading to inactivation of activated clotting factors, particularly factor Xa and to a lesser extent thrombin. This prevents thrombus formation and propagation. It is administered subcutaneously and has predictable pharmacokinetics compared to unfractionated heparin.","oneSentence":"Dalteparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:44:12.917Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Venous thromboembolism prophylaxis"},{"name":"Treatment of deep vein thrombosis and pulmonary embolism"},{"name":"Acute coronary syndrome"}]},"trialDetails":[{"nctId":"NCT04483960","phase":"PHASE3","title":"Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2020-07-28","conditions":"SARS-CoV-2 Infection (COVID-19)","enrollment":2200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"(Arm Closed) Dalteparin","genericName":"(Arm Closed) Dalteparin","companyName":"University of Melbourne","companyId":"university-of-melbourne","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dalteparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin. Used for Venous thromboembolism prophylaxis, Treatment of deep vein thrombosis and pulmonary embolism, Acute coronary syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}